Reduction in Migraine Frequency (amitriptyline and topiramate) 4 week baseline period to last 4 weeks of the 24-week trial [clinicaltrials_resource:2c7f7d571c539c46f29dd160750ee284]
To test if amitriptyline and topiramate are superior to placebo in reducing migraine frequency, as defined by the percentage of subjects with a 50% reduction in the number of migraine days per month, in children and adolescents ages 8-17.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Reduction in Migraine Frequency (amitriptyline and topiramate) 4 week baseline period to last 4 weeks of the 24-week trial [clinicaltrials_resource:2c7f7d571c539c46f29dd160750ee284]
To test if amitriptyline and topiramate are superior to placebo in reducing migraine frequency, as defined by the percentage of subjects with a 50% reduction in the number of migraine days per month, in children and adolescents ages 8-17.
Bio2RDF identifier
2c7f7d571c539c46f29dd160750ee284
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2c7f7d571c539c46f29dd160750ee284
measure [clinicaltrials_vocabulary:measure]
Reduction in Migraine Frequency (amitriptyline and topiramate)
time frame [clinicaltrials_vocabulary:time-frame]
4 week baseline period to last 4 weeks of the 24-week trial
description
To test if amitriptyline and t ...... ren and adolescents ages 8-17.
identifier
clinicaltrials_resource:2c7f7d571c539c46f29dd160750ee284
title
Reduction in Migraine Frequenc ...... t 4 weeks of the 24-week trial
@en
type
label
Reduction in Migraine Frequenc ...... f7d571c539c46f29dd160750ee284]
@en